Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
RNA Editing Pionee | Korro Bio leads in RNA editing technology, with KRRO-110 for AATD treatment. Explore the potential of this groundbreaking approach in genetic disorders. |
Clinical Milestones | Delve into KRRO-110's Phase 1/2a REWRITE study. Learn about upcoming data releases and their potential impact on Korro Bio's market valuation. |
Financial Outlook | Discover Korro Bio's strategic moves to extend cash runway. Analysts set price targets ranging from $74 to $180, reflecting varied market expectations. |
Market Positioning | Uncover Korro Bio's competitive edge in the AATD treatment landscape. Examine the company's potential to revolutionize multiple therapeutic areas. |
Metrics to compare | KRRO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKRROPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.5x | −6.5x | −0.7x | |
PEG Ratio | −0.13 | −0.04 | 0.00 | |
Price/Book | 3.6x | 0.0x | 2.6x | |
Price / LTM Sales | 65.3x | 20.4x | 3.4x | |
Upside (Analyst Target) | 100.2% | 254.8% | 36.2% | |
Fair Value Upside | Unlock | −7.8% | 4.1% | Unlock |